This is a multi-center, cross-sectional study to assess risk for liver fibrosis and hepatic injury in individuals with urea cycle disorders (UCDs) using serum biomarkers, Fibroscan, and MRE. This study will be conducted at 5 sites of the Urea Cycle Disorders Consortium: Baylor College of Medicine in Houston, TX, Seattle Children's Hospital in Seattle, WA, Children's Hospital Colorado in Aurora, CO, Children's Hospital of Philadelphia in Philadelphia, PA, and Children's National Medical Center in Washington D.C.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Fibrotest
Timeframe: One measurement made on the 1 day of the study visit (stage A)
Fibroscan (liver stiffness)
Timeframe: One measurement made on the 1 day of the study visit (stage A)
Fibroscan (CAP)
Timeframe: One measurement made on the 1 day of the study visit (stage A)
MRE
Timeframe: One measurement made on the 1 day of the study visit (stage B)